| |
| |
|
| Insider
Information: |
Hassan Fred |
| Relationship: |
Director |
| City: |
Kenilworth |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
2,176,602 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$7,217,161 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
2,176,602 |
|
|
| Total
Value |
$7,217,161 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-2.0
|
0.0
|
| Percentage
Gain/Loss : |
 -18.1%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Merck & Co Inc |
MRK |
Chairman and CEO, Dire... |
2009-11-03 |
0 |
2003-11-26 |
0 |
Premium* |
|
|
Avon Products Inc |
AVP |
Director |
2011-02-25 |
49,079 |
2004-05-06 |
0 |
Premium* |
|
|
Time Warner Inc |
TWX |
|
2018-06-14 |
0 |
2010-03-03 |
0 |
Premium* |
|
|
Bausch Health Companies Inc |
BHC |
Director |
2013-08-29 |
53,969 |
2013-08-22 |
0 |
Premium* |
|
|
Amgen Inc |
AMGN |
Director |
2020-05-05 |
9,191 |
2015-08-04 |
0 |
Premium* |
|
|
Precigen Inc |
PGEN |
Director |
2024-03-14 |
1,029,834 |
2016-12-01 |
0 |
Premium* |
|
|
Bridgebio Pharma, Inc. |
BBIO |
Director |
2021-12-29 |
19,300 |
2021-12-29 |
0 |
Premium* |
|
|
Cocrystal Pharma |
COCP |
Director |
2023-04-20 |
1,015,229 |
|
0 |
Premium* |
|
|
Prometheus Biosciences, Inc. |
RXDX |
Director |
2023-06-16 |
0 |
2023-05-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
55 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMGN |
Amgen Inc |
Director |
• • – |
2015-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
572 |
572 |
0 |
- |
|
| AMGN |
Amgen Inc |
Director |
• • – |
2015-08-19 |
4 |
B |
$165.50 |
$501,562 |
D/D |
3,010 |
3,582 |
2.39 |
- |
|
| AMGN |
Amgen Inc |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
4,861 |
0 |
- |
|
| AMGN |
Amgen Inc |
Director |
• • – |
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
6,091 |
0 |
- |
|
| AMGN |
Amgen Inc |
Director |
• • – |
2018-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,127 |
7,218 |
0 |
- |
|
| AMGN |
Amgen Inc |
Director |
• • – |
2019-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,127 |
8,345 |
0 |
- |
|
| AMGN |
Amgen Inc |
Director |
• • – |
2020-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
846 |
9,191 |
0 |
- |
|
| AVP |
Avon Products Inc |
Director |
– • – |
2004-05-06 |
4 |
A |
$81.27 |
$35,027 |
D/D |
431 |
13,250 |
|
- |
|
| AVP |
Avon Products Inc |
Director |
– • – |
2005-05-05 |
4 |
A |
$39.87 |
$35,006 |
D/D |
878 |
27,378 |
|
- |
|
| AVP |
Avon Products Inc |
Director |
– • – |
2006-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
3,182 |
30,560 |
|
- |
|
| AVP |
Avon Products Inc |
Director |
– • – |
2007-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,519 |
33,079 |
0 |
- |
|
| AVP |
Avon Products Inc |
Director |
– • – |
2010-02-19 |
4 |
OE |
$19.12 |
$152,960 |
D/D |
8,000 |
41,079 |
0 |
- |
|
| AVP |
Avon Products Inc |
Director |
– • – |
2011-02-25 |
4 |
OE |
$21.56 |
$172,480 |
D/D |
8,000 |
49,079 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
– • – |
2013-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,969 |
2,969 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
– • – |
2013-08-29 |
4 |
B |
$99.01 |
$5,049,459 |
D/D |
51,000 |
53,969 |
2.39 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
Director |
– • – |
2021-12-29 |
4 |
B |
$14.17 |
$273,390 |
D/D |
19,300 |
19,300 |
2.39 |
% |
|
| COCP |
Cocrystal Pharma |
Director |
– • – |
2023-04-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,015,229 |
|
% |
|
| MRK |
Merck & Co Inc |
Chairman and CEO |
• • – |
2003-11-26 |
4/A |
B |
$15.32 |
$4,679,170 |
D/D |
303,500 |
503,500 |
2.81 |
- |
|
| MRK |
Merck & Co Inc |
Chairman and CEO |
• – – |
2003-11-26 |
4 |
A |
$15.32 |
$4,679,170 |
D/D |
303,500 |
503,500 |
|
- |
|
| MRK |
Merck & Co Inc |
Chairman and CEO |
• • – |
2006-12-01 |
4 |
D |
$21.93 |
$2,032,911 |
D/D |
(92,700) |
610,800 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Chairman and CEO |
• • – |
2006-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
200,000 |
703,500 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Chairman and CEO |
• • – |
2008-04-24 |
4 |
B |
$18.21 |
$2,008,774 |
D/D |
110,000 |
720,800 |
2.81 |
- |
|
| MRK |
Merck & Co Inc |
Chairman and CEO |
• • – |
2008-04-25 |
4 |
D |
$18.64 |
$1,727,928 |
D/D |
(92,700) |
828,100 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Chairman and CEO |
• • – |
2008-04-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
200,000 |
920,800 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Chairman and CEO |
• • – |
2009-04-01 |
4 |
D |
$23.70 |
$2,196,990 |
D/D |
(92,700) |
935,400 |
0 |
- |
|
55 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
